Biothera Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biothera's estimated annual revenue is currently $7.8M per year.(i)
  • Biothera's estimated revenue per employee is $155,000

Employee Data

  • Biothera has 50 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.5M74-9%N/AN/A
#2
$14.4M93-8%$20.5MN/A
#3
$13.8M89-5%N/AN/A
#4
$4.3M28N/AN/AN/A
#5
$7.4M48-11%$6.4MN/A
#6
$9.5M61N/AN/AN/A
#7
$2.5M167%N/AN/A
#8
$984.6M260012%N/AN/A
#9
$4M26N/AN/AN/A
#10
$4.3M28N/A$37.6MN/A

Biothera Pharmaceuticals is a privately held, clinical stage immuno-oncology company developing our proprietary immunotherapy, Imprime PGG, in combination with immune checkpoint inhibitors, or CPIs, for multiple cancer indications. Imprime PGG is a biologic innate immune modulator that activates the immune system and coordinates anti-cancer immune responses that result in increased activation of cancer-specific T cells. Preclinical studies demonstrate that Imprime PGG can enhance the efficacy of anti-cancer immune responses in combination with CPI, tumor-targeting and anti-angiogenic antibodies. The Company has clinical research agreements with Merck, Genentech and AstraZeneca to evaluate Imprime PGG in combination with CPIs in multiple cancer indications, including metastatic triple negative breast cancer, head and neck cancer and colorectal cancer. Imprime PGG has shown strong evidence of tolerability in clinical trials with more than 500 subjects, including over 400 cancer patients. For more information, visit us at www.biothera.com.

keywords:N/A

N/A

Total Funding

50

Number of Employees

$7.8M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.4M546%N/A
#2
$13.6M56N/AN/A
#3
$14.6M660%N/A
#4
$15.1M695%N/A
#5
$19.5M71-25%N/A